Skip to main content
Toggle navigation
Login
Search
Home
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Live Streamed
On Demand
Back
Favorite
Facebook
Tweet
Print
Changlin Ai, Master of Medicine
TenNor Therapeutics (Suzhou) Ltd, China
Disclosure(s): TenNor Therapeutics (Suzhou) Ltd: Employee
Poster(s):
(P-1064) Safety, Tolerability, and Pharmacokinetics of Rifaquizone for Injection in Healthy Participants in China: A Single-center, Double-blind, Randomized, Placebo-controlled, Phase 1 Bridge Study
Friday, October 18, 2024
12:15 PM – 1:30 PM
US PT
(P-1090) Rifaquizinone for the Treatment of Acute Bacterial Skin and Skin Structure Infections: A Multicenter, Double-Blind, Randomized, Active-Controlled, Phase 2 Trial
Friday, October 18, 2024
12:15 PM – 1:30 PM
US PT
(P-1116) Distribution of Rifaquizinone in Bone, Synovial Fluid and Plasma: A Phase 1 Trial in Patients Undergoing Total Hip or Knee Arthroplasty
Friday, October 18, 2024
12:15 PM – 1:30 PM
US PT
(P-1117) An Open-label Phase 1 Study in Healthy Adult Male Participants to Investigate the Absorption, Metabolism, and Excretion of [
14
C]-Rifaquizinone Following a Single Intravenous Administration
Friday, October 18, 2024
12:15 PM – 1:30 PM
US PT
